Crohn's Disease Full Disease Coverage: Updated 2017 Research Report - ResearchAndMarkets.com

DUBLIN--()--The "Crohn's Disease: Full Disease Coverage" report has been added to ResearchAndMarkets.com's offering.

Crohn's disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn's disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn's disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Market Snapshot

  • Stelara is set to become the leading brand in Crohn's disease as the longstanding anti-TNFs face biosimilar competition.
  • Infliximab - Remicade and its biosimilar versions - remains the most frequently prescribed biologic by surveyed physicians.
  • Crohn's disease is an expanding global health problem, with prevalent cases forecasted to increase in the majority of analyzed countries.
  • Gastroenterologists intend to prescribe Stelara over Entyvio due to its faster onset of action and comparable safety.
  • Mongersen's oral formulation and favorable safety will drive prescribing, despite its overall modest efficacy to date.

Key Topics Covered:

FORECAST: CROHN'S DISEASE

Executive Summary

Market Overview and Trends

Market Definition and Methodology

Cimzia (certolizumab pegol)

Cx601

Entyvio (vedolizumab)

etrolizumab

filgotinib

Humira (adalimumab)

mongersen (GED 0301)

Remicade (infliximab)

Stelara (ustekinumab)

Tysabri (natalizumab)

Primary Research Methodology

TREATMENT: CROHN'S DISEASE

Executive Summary

Primary Research Methodology

Patient Segmentation

Current Treatment Options

Prescribing Trends

Compliance

Unmet Needs in Crohn's Disease

Prescribing Influences

Impact of Biosimilars

EPIDEMIOLOGY: CROHN'S DISEASE

Executive Summary

Disease Background

Sources and Methodology

Forecast

Epidemiologist Insight

Strengths and Limitations

Appendix

MARKETED DRUGS: CROHN'S DISEASE

Executive Summary

Product Overview

Product profile: Cimzia

Product profile: Entyvio

Product profile: Humira

Product profile: Remicade

Product profile: Stelara

Product profile: Tysabri

PIPELINE: CROHN'S DISEASE

Executive Summary

Clinical Pipeline Overview

Comparator Therapy

Product profile (late stage): Cx601

Product profile (late stage): etrolizumab

Product profile (late stage): filgotinib

Product profile (late stage): mongersen

For more information about this report visit https://www.researchandmarkets.com/research/4sdz7d/crohns_disease?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy and Immunology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Allergy and Immunology